Inactive Instrument

Press Releases Neuroderm Ltd

Equities

IL0011334955

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

NeuroDerm Shareholders Approve Proposed Acquisition by Mitsubishi Tanabe Pharma Corporation	17-09-12	GL
Neuroderm : Stocks Under Scanner in the Biotech Space -- Merrimack Pharma, MannKind, NeuroDerm, and Celsion	17-08-23	PR
NeuroDerm Announces Second Quarter 2017 Financial Results	17-08-03	GL
NeuroDerm Announces Extraordinary General Meeting of Shareholders to Approve Acquisition by Mitsubishi Tanabe Pharma Corporation	17-08-01	GL
NeuroDerm Enters Definitive Agreement to be Acquired by Mitsubishi Tanabe Pharma Corporation for US$1.1 Billion in Cash	17-07-24	GL
Results of NeuroDerm’s ND0612H Phase II Trial Presented in Oral Session at the 3rd Congress of the European Academy of Neurology	17-06-27	GL
NeuroDerm Presents Six Posters at the 21st International Congress of Parkinson’s Disease and Movement Disorders	17-06-08	GL
European Medicines Agency Accepts Design of NeuroDerm’s ND0612 Phase III iNDiGO Efficacy Trial	17-06-06	GL
NeuroDerm Presents ND0612H Phase II Trial Results in Late-Breaking Poster Session at the 21st International Congress of Parkinson’s Disease and Movement Disorders	17-06-05	GL
NeuroDerm CEO to Present at the Jefferies Global Healthcare Conference on June 7, 2017	17-05-30	GL
NeuroDerm ND0612H Phase II Trial Results to be Presented in Late-Breaking Session at the 21st International Congress of Parkinson’s Disease and Movement Disorders	17-05-23	GL
NeuroDerm Announces First Quarter 2017 Financial Results	17-05-11	GL
NeuroDerm to Ring the Nasdaq Stock Market Opening Bell and Participate in the Parkinson’s Unity Walk	17-04-20	GL
NeuroDerm to Host Investor Day on April 21, 2017	17-04-10	GL
NeuroDerm Announces Fourth Quarter and Full Year 2016 Financial Results	17-03-30	GL
NeuroDerm to Host Fourth Quarter and 2016 Fiscal Year Financial Results Conference Call on March 30, 2017	17-03-21	GL
NeuroDerm Achieves Primary Endpoint in ND0612H Phase II Trial for Advanced Parkinson’s Disease; Seeks Broader EU Label Based on iNDiGO Trial Following EMA Meeting	17-03-01	GL
NeuroDerm CEO to Present at Upcoming Investor Conferences	17-02-27	GL
NeuroDerm Announces Extraordinary General Meeting of Shareholders	17-01-26	GL
NeuroDerm CEO to Present at the 35th Annual J.P. Morgan Healthcare Conference on January 12, 2017	17-01-03	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Neuroderm Ltd

Equities

IL0011334955

Press Releases

Filters